Starbucks Upgraded to Outperform, Doximity Cut to Sell

Key analyst calls on May 14, 2026, saw Wall Street sentiment diverge on two major U.S. companies. TD Cowen upgraded Starbucks (SBUX) to 'Outperform' from 'Market Perform', issuing a new price target of $95 per share. In a contrasting move, Morgan Stanley downgraded Doximity (DOCS) to 'Underweight' from 'Equal Weight', citing concerns over slowing growth in the digital health advertising sector and cutting its price target to $22.

Why TD Cowen Upgraded Starbucks Stock (SBUX)

TD Cowen's upgrade of Starbucks centers on renewed confidence in the company's 'Triple Shot Reinvention' strategy. The plan focuses on enhancing store efficiency, accelerating mobile order and pay, and improving the employee experience to reduce turnover. The firm noted that early results from these initiatives are improving store-level throughput by over 5% during peak hours, directly impacting revenue.

The analyst report highlighted a stabilizing outlook for Starbucks' China operations, which have been a source of investor concern. After a period of volatility, same-store sales growth in the region is projected to return to a positive trajectory in the second half of the year. This recovery, combined with steady growth in North America, provides a clearer path to achieving the company's fiscal year earnings targets of $3.85 EPS.

Valuation was a key component of the upgrade. With the stock having pulled back nearly 15% year-to-date, TD Cowen argued that the risk/reward profile is now favorable. The new $95 price target implies a forward price-to-earnings (P/E) ratio of approximately 24.7x, which the firm sees as a reasonable premium for a brand with Starbucks' global reach and improving operational metrics.

What is the Outlook for Starbucks' Growth?

The company's digital ecosystem remains a primary growth driver. The Starbucks Rewards loyalty program now counts over 35 million active members in the U.S., who on average spend three times more than non-members. Continued innovation in personalized offers and mobile ordering is expected to deepen this engagement and support long-term sales growth.

However, a significant risk acknowledged in the analyst note is the impact of persistent inflation on consumer discretionary spending. If macroeconomic conditions worsen, even loyal customers may reduce the frequency of their visits or trade down to lower-priced items. This could pressure same-store sales and challenge the premium valuation the stock has historically commanded. Investors should monitor consumer confidence indices for signs of weakness.

International expansion beyond China also presents a substantial opportunity. Starbucks is actively growing its footprint in markets like India, Southeast Asia, and Latin America. These regions offer long-term unit growth potential, with the company planning to open over 1,500 net new stores globally in the current fiscal year. Successful execution in these diverse markets is critical for sustaining momentum.

Why Morgan Stanley Downgraded Doximity (DOCS)

Morgan Stanley's downgrade of Doximity reflects mounting concerns about a slowdown in its core market: digital advertising for the pharmaceutical and healthcare industries. The firm's channel checks suggest that major pharmaceutical companies are scrutinizing their marketing budgets amid patent cliffs and a focus on cost controls. This environment reduces the near-term revenue visibility for Doximity, which relies heavily on these clients.

The downgrade to 'Underweight' signals a belief that the stock will likely underperform the broader market over the next 12 to 18 months. The analyst report pointed to decelerating revenue growth, which has fallen from over 40% two years ago to a projected 12% for the upcoming fiscal year. This slowdown makes it difficult to justify the stock's premium valuation multiples.

Competition is another factor cited in the report. While Doximity has a strong network effect with over 80% of U.S. physicians on its platform, other digital health and medical communications companies are vying for the same advertising dollars. This increased competition could put pressure on Doximity's pricing power and market share over the long term.

How Does Doximity's Valuation Look Now?

The price target reduction to $22 from a previous $28 reflects the lowered growth expectations. This new target is based on a revised enterprise value-to-sales multiple of approximately 5.5x, a significant contraction from its historical average. Morgan Stanley argues this lower multiple is necessary given the maturation of the digital health advertising market post-pandemic.

Despite the downgrade, the firm acknowledges Doximity's strong profitability and dominant market position among healthcare professionals. The platform remains an essential tool for physician communication and networking. The challenge lies in monetizing this extensive network beyond pharmaceutical advertising, an area where the company has yet to demonstrate significant traction.

Q: What is the Starbucks 'Triple Shot Reinvention' plan?

A: The 'Triple Shot Reinvention' is Starbucks' multi-year strategic plan announced in late 2025. It has three main pillars: elevating the brand through product innovation, strengthening digital capabilities with a focus on its loyalty program, and making the company more efficient. A key goal is to unlock $3 billion in cost savings over three years, which the company plans to reinvest into employee wages, store improvements, and technology to drive future growth.

Q: Who are Doximity's main competitors?

A: Doximity operates in a niche but increasingly competitive space. Its direct competitors include Medscape, which is owned by WebMD and also offers medical news and education to physicians. It also faces indirect competition from broader professional networks like LinkedIn, as well as specialized healthcare technology platforms that connect doctors with pharmaceutical companies for marketing and research purposes. The competitive pressure comes from entities vying for physician engagement and pharmaceutical marketing budgets.

Bottom Line

Analyst sentiment shifted on May 14, favoring Starbucks' operational turnaround while expressing caution on Doximity's near-term growth prospects.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.